ALSEN Sensorion SA
6.296EUR+0.25%Mkt Cap: 70.53M $P/E: —Today
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy developm…
Industry Peers
Biotechnology$127.24BUSDP/E 29.3
$76.05BUSDP/E 18.3
$74.84BUSD
$56.77BUSDP/E 37.1
$58.21BUSDP/E 35.5
$41.93BUSDP/E 17.9
$42.84BUSD
$41.27BUSDP/E 64.9
$32.61BUSDP/E 30.0
$29.97BUSDP/E 37.8
$25.66BUSD
$24.05BUSD
$23.24BUSDP/E 29.8
$22.98BUSD
$22.23BUSDP/E 30.6
$22.85BUSDP/E 14.4
$15.02BUSDP/E 15.9
$14.87BUSDP/E 17.3
$14.45BUSDP/E 18.4
$13.81BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
AAudio infos 365 | ||
 Sensorion (ENXTPA:ALSEN) Could Be 34% Overvalued After Reverse Share Split Sensorion (ENXTPA:ALSEN) has completed a reverse share split, exchanging every 50 existing shares for 1 new share. The consolidated stock is now trading in Paris under a new ISIN. Recent trading shows Sensorion under pressure, with the share price at €9.70 after declines of about 7% over one day, 19% over the past week and 34% across the last month. This continues a longer pattern of weak total shareholder returns over one, three and five years. This softer momentum sits alongside the new... | ||
LL'Agefi | ||
MMyPharma Editions | ||
LL'Ouïe Magazine | ||